Cargando…
Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia
BACKGROUND: Numerous economic models have assessed the cost-effectiveness of antipsychotic medications in schizophrenia. It is important to understand what key impacts of antipsychotic medications were considered in the existing models and limitations of existing models in order to inform the develo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351140/ https://www.ncbi.nlm.nih.gov/pubmed/32649663 http://dx.doi.org/10.1371/journal.pone.0234996 |
_version_ | 1783557391841755136 |
---|---|
author | Jin, Huajie Tappenden, Paul Robinson, Stewart Achilla, Evanthia Aceituno, David Byford, Sarah |
author_facet | Jin, Huajie Tappenden, Paul Robinson, Stewart Achilla, Evanthia Aceituno, David Byford, Sarah |
author_sort | Jin, Huajie |
collection | PubMed |
description | BACKGROUND: Numerous economic models have assessed the cost-effectiveness of antipsychotic medications in schizophrenia. It is important to understand what key impacts of antipsychotic medications were considered in the existing models and limitations of existing models in order to inform the development of future models. OBJECTIVES: This systematic review aims to identify which clinical benefits, clinical harms, costs and cost savings of antipsychotic medication have been considered by existing models, to assess quality of existing models and to suggest good practice recommendations for future economic models of antipsychotic medications. METHODS: An electronic search was performed on multiple databases (MEDLINE, EMBASE, PsycInfo, Cochrane database of systematic reviews, The NHS Economic Evaluation Database and Health Technology Assessment database) to identify economic models of schizophrenia published between 2005–2020. Two independent reviewers selected studies for inclusion. Study quality was assessed using the National Institute for Health and Care Excellence (NICE) checklist and the Cooper hierarchy. Key impacts of antipsychotic medications considered by exiting models were descriptively summarised. RESULTS: Sixty models were included. Existing models varied greatly in key impacts of antipsychotic medication included in the model, especially in clinical outcomes used for assessing reduction in psychotic symptoms and types of adverse events considered in the model. Quality of existing models was generally low due to failure to capture the health and cost impact of adverse events of antipsychotic medications and input data not obtained from best available source. Good practices for modelling antipsychotic medications are suggested. DISCUSSIONS: This review highlights inconsistency in key impacts considered by different models, and limitations of the existing models. Recommendations on future research are provided. |
format | Online Article Text |
id | pubmed-7351140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-73511402020-07-20 Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia Jin, Huajie Tappenden, Paul Robinson, Stewart Achilla, Evanthia Aceituno, David Byford, Sarah PLoS One Research Article BACKGROUND: Numerous economic models have assessed the cost-effectiveness of antipsychotic medications in schizophrenia. It is important to understand what key impacts of antipsychotic medications were considered in the existing models and limitations of existing models in order to inform the development of future models. OBJECTIVES: This systematic review aims to identify which clinical benefits, clinical harms, costs and cost savings of antipsychotic medication have been considered by existing models, to assess quality of existing models and to suggest good practice recommendations for future economic models of antipsychotic medications. METHODS: An electronic search was performed on multiple databases (MEDLINE, EMBASE, PsycInfo, Cochrane database of systematic reviews, The NHS Economic Evaluation Database and Health Technology Assessment database) to identify economic models of schizophrenia published between 2005–2020. Two independent reviewers selected studies for inclusion. Study quality was assessed using the National Institute for Health and Care Excellence (NICE) checklist and the Cooper hierarchy. Key impacts of antipsychotic medications considered by exiting models were descriptively summarised. RESULTS: Sixty models were included. Existing models varied greatly in key impacts of antipsychotic medication included in the model, especially in clinical outcomes used for assessing reduction in psychotic symptoms and types of adverse events considered in the model. Quality of existing models was generally low due to failure to capture the health and cost impact of adverse events of antipsychotic medications and input data not obtained from best available source. Good practices for modelling antipsychotic medications are suggested. DISCUSSIONS: This review highlights inconsistency in key impacts considered by different models, and limitations of the existing models. Recommendations on future research are provided. Public Library of Science 2020-07-10 /pmc/articles/PMC7351140/ /pubmed/32649663 http://dx.doi.org/10.1371/journal.pone.0234996 Text en © 2020 Jin et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Jin, Huajie Tappenden, Paul Robinson, Stewart Achilla, Evanthia Aceituno, David Byford, Sarah Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia |
title | Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia |
title_full | Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia |
title_fullStr | Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia |
title_full_unstemmed | Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia |
title_short | Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia |
title_sort | systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351140/ https://www.ncbi.nlm.nih.gov/pubmed/32649663 http://dx.doi.org/10.1371/journal.pone.0234996 |
work_keys_str_mv | AT jinhuajie systematicreviewofthemethodsofhealtheconomicmodelsassessingantipsychoticmedicationforschizophrenia AT tappendenpaul systematicreviewofthemethodsofhealtheconomicmodelsassessingantipsychoticmedicationforschizophrenia AT robinsonstewart systematicreviewofthemethodsofhealtheconomicmodelsassessingantipsychoticmedicationforschizophrenia AT achillaevanthia systematicreviewofthemethodsofhealtheconomicmodelsassessingantipsychoticmedicationforschizophrenia AT aceitunodavid systematicreviewofthemethodsofhealtheconomicmodelsassessingantipsychoticmedicationforschizophrenia AT byfordsarah systematicreviewofthemethodsofhealtheconomicmodelsassessingantipsychoticmedicationforschizophrenia |